Vaginal ring tested for safety in overweight PCOS women

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of PCOS according to Rotterdam criteria, with at least 2 of 3 of the following criteria: oligomenorrhea (≤8 periods per year), clinical or biochemical hyperandrogenism, and polycystic ovaries on ultrasound * Body mass index ≥25 and ≤45 kg/m2 * In good general health according to the investigators' discretion * Willing to avoid pregnancy for the duration of the study Exclusion Criteria: * Current pregnancy or desire for pregnancy during course of study * Current breastfeeding * Second-trimester pregnancy within four weeks prior to initiation of NuvaRing or third-trimester pregnancy within 6 months prior to initiation of NuvaRing * Use of hormonal contraception within four weeks prior to initiation of NuvaRing * Diagnosis of metabolic syndrome. Metabolic syndrome will be defined according to the updated Adult Treatment Panel III as 3 or more of the following criteria: blood pressure ≥130/85 mm Hg, waist circumference \>35 inches, fasting glucose ≥110 mg/dL, TG ≥150 mg/dL, HDL-C \<50 mg/dL. * Contraindications to NuvaRing use: * Age ≥ 35 plus tobacco use * Current or past deep vein thrombosis or pulmonary embolism * Cerebrovascular disease * Coronary artery disease * Thrombogenic valvular or rhythm diseases of the heart (such as subacute bacterial endocarditis with valvular disease or atrial fibrillation) * Inherited or acquired coagulopathy * Headaches with focal neurological symptoms or migraine headaches with aura * Age ≥ 35 plus any migraine headaches * Liver tumors, benign or malignant * Undiagnosed abnormal uterine bleeding * Current or past breast cancer or other estrogen- or progestin-sensitive cancer * Hypersensitivity to any of the components of NuvaRing * Use of hepatitis C drug combinations containing ombitasvir/paritaprevir/ritonavir * Medical comorbidities: * 21-hydroxylase deficiency, congenital adrenal hyperplasia * Untreated thyroid disease * Untreated hyperprolactinemia * Type 1 or 2 diabetes mellitus * Uncontrolled liver disease * Uncontrolled renal disease * Current alcohol abuse * Hypertension ≥ 140 mm Hg average systolic or ≥ 90 mm Hg average diastolic in women using anti-hypertensive medication * Hypertension ≥ 150 mm Hg average systolic or ≥ 100 mm Hg average diastolic in women not using anti-hypertensive medication * History of or current gynecologic cancer * Triglycerides \>=250 mg/dL * Current use of lipid-lowering or weight loss agents * Participation in any study of an investigational drug or device or biologic agent within 30 days * Suspected adrenal or ovarian tumor secreting androgens * Suspected Cushing's syndrome * Bariatric surgery within 12 months * Other medical concerns that in the judgment of the investigator may compromise safety of the participant or confound the reliability of compliance and information acquired in this study